Differential outcome of tolerance induction in naive versus activated Theiler's virus epitope-specific CD8+ cytotoxic T cells

Journal of Virology

Volumn 81, Issue 12, 2007, Pages 6584-6593

  Getts, Meghann Teague ^a   Kim, Byung S ^a   Miller, Stephen D ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; EPITOPE; ETHYLENE CARBODIIMIDE; IMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; MOUSE; MULTIPLE SCLEROSIS; MURINE ENCEPHALOMYELITIS VIRUS; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIGEN-PRESENTING CELLS; AUTOIMMUNE DISEASES; CARBODIIMIDES; CD8-POSITIVE T-LYMPHOCYTES; CENTRAL NERVOUS SYSTEM; CYTOKINES; EPITOPES; FLOW CYTOMETRY; HUMANS; IMMUNE TOLERANCE; MICE; MICE, INBRED C57BL; SPLEEN; THEILOVIRUS;

MUS; THEILER'S ENCEPHALOMYELITIS VIRUS;

EID: 34249950141     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.00008-07     Document Type: Article

References (41)

1. b-/- mice are susceptible to persistent infection by Theiler's virus. J. Virol. 74:5470-5476.
2. b genes in resistance to persistent Theiler's murine encephalomyelitis virus infection of the central nervous system. J. Gen. Virol. 82:1043-1047.
3. + T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J. Exp. Med. 192:393-404.
4. Blanco, P., J. F. Viallard, J. L. Pellegrin, and J. F. Moreau. 2005. Cytotoxic T lymphocytes and autoimmunity. Curr. Opin. Rheumatol. 17:731-734.
5. Brahic, M. 2002. Theiler's virus infection of the mouse, or: of the importance of studying animal models. Virology 301:1-5.
6. Brahic, M., and A. Buret. 1998. Genetics of susceptibility to Theiler's virus infection. Bioessays 20:627-633.
7. Campbell, I. L., C. R. Abraham, E. Masliah, P. Kemper, J. D. Inglis, M. B. Oldstone, and L. Mucke. 1993. Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proc. Natl. Acad. Sci. USA 90:10061-10065.
8. Chen, W., L. C. Anton, J. R. Bennink, and J. W. Yewdell. 2000. Dissecting the multifactorial causes of immunodominance in class I-restricted T cell responses to viruses. Immunity 12:83-93.
9. Clatch, R. J., R. W. Melvold, S. D. Miller, and H. L. Lipton. 1985. Theiler's murine encephalomyelitis virus (TMEV)-induced demyelinating disease in mice is influenced by the H-2D region: correlation with TMEV-specific delayed-type hypersensitivity. J. Immunol. 135:1408-1414.
10. Compston, A., and A. Coles. 2002. Multiple sclerosis. Lancet 359:1221-1231.
11. Ferran, C., K. Sheehan, M. Dy, R. Schreiber, S. Merite, P. Landais, L. H. Noel, G. Grau, J. Bluestone, and J. F. Bach. 1990. Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation. Eur. J. Immunol. 20:509-515.
12. Fiette, L., C. Aubert, M. Brahic, and C. Pena Rossi. 1993. Theiler's virus infection of β2-microglobulin-deficient mice. J. Virol. 67:589-592.
13. Hirsch, R., R. E. Gress, D. H. Pluznik, M. Eckhaus, and J. A. Bluestone. 1989. Effects of in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice. II. In vivo activation of T cells. J. Immunol. 142:737-743.
14. + T cells mediate a peptide-induced fatal syndrome. J. Immunol. 174:6854-6862.
15. + T cells. Virology 340:84-94.
16. Kappos, L., G. Comi, H. Panitch, J. Oger, J. Antel, P. Conlon, and L. Steinman. 2000. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. Nat. Med. 6:1176-1182.
17. Kennedy, M. K., L. J. Tan, M. C. Dal Canto, and S. D. Miller. 1990. Regulation of the effector stages of experimental autoimmune encephalomyelitis via neuroantigen-specific tolerance induction. J. Immunol. 145:117-126.
18. Kennedy, M. K., L. J. Tan, M. C. Dal Canto, V. K. Tuohy, Z. J. Lu, J. L. Trotter, and S. D. Miller. 1990. Inhibition of murine relapsing experimental autoimmune encephalomyelitis by immune tolerance to proteolipid protein and its enccphalitogenic peptides. J. Immunol. 144:909-915.
19. Liblau, R. S., F. S. Wong, L. T. Mars, and P. Santamaria. 2002. Autoreactive CD8 T cells in organ-specific autoimmunity: emerging targets for therapeutic intervention. Immunity 17:1-6.
20. + T cells in autoimmune diabetes. Proc. Natl. Acad. Sci. USA 100:8384-8388.
21. Lipton, H. L., R. Melvold, S. D. Miller, M. C. Dal Canto, and K. Jensen. 1995. Mutation of a major histocompatibility class I locus, H-2D, leads to an increased virus burden and disease susceptibility in Theiler's virus-induced demyelinating disease. J. Neurovirol. 1:138-144.
22. Liu, F., R. Feuer, D. E. Hassett, and J. L. Whitton. 2006. Peptide vaccination of mice immune to LCMV or vaccinia virus causes serious CD8 T cell-mediated, TNF-dependent immunopathology. J. Clin. Investig. 116:465-475.
23. b-restrictcd regions of the BeAn strain of Theiler's virus and exhibit different cytokine profiles. J. Virol. 76:3125-3134.
24. + T cell response against a single immunodominant viral peptide. Eur. J. Immunol. 33:2501-2510.
25. Miller, S. D., R. P. Wetzig, and H. N. Claman. 1979. The induction of cell-mediated immunity and tolerance with protein antigens coupled to syngeneic lymphoid cells. J. Exp. Med. 149:758-773.
26. Neumann, H., I. M. Medana, J. Bauer, and H. Lassmann. 2002. Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci. 25:313-319.
27. Palma, J. P., H. G. Lee, M. Mohindru, B. S. Kim, M. C. Dal Canto, S. D. Miller, and B. S. Kim. 2001. Enhanced susceptibility to Theiler's virus-induced demyelinating disease in perforin-deficient mice. J. Neuroimmunol. 116:25-35.
28. Pion, S., G. J. Christianson, P. Fontaine, D. C. Roopenian, and C. Perreault. 1999. Shaping the repertoire of cytotoxic T-lymphocyte responses: explanation for the immunodominance effect whereby cytotoxic T lymphocytes specific for immunodominant antigens prevent recognition of nondominant antigens. Blood 93:952-962.
29. Pion, S., P. Fontaine, M. Desaulniers, J. Jutras, J. G. Filep, and C. Perreault. 1997. On the mechanisms of immunodominance in cytotoxic T lymphocyte responses to minor histocompatibility antigens. Eur. J. Immunol. 27:421-430.
30. Probert, L., K. Akassoglou, M. Pasparakis, G. Kontogeorgos, and G. Kollias. 1995. Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor-alpha. Proc. Natl. Acad. Sci. USA 92:11294-11298.
31. Pullen, L. C., S. D. Miller, M. C. Dal Canto, and B. S. Kim. 1993. Class 1-deficient resistant mice intracerebrally inoculated with Theiler's virus show an increased T cell response to viral antigens and susceptibility to demyelination. Eur. J. Immunol. 23:2287-2293.
32. Rodriguez, M., and C. S. David. 1985. Demyelination induced by Theiler's virus: influence of the H-2 haplotype. J. Immunol. 135:2145-2148.
33. Rodriguez, M., A. J. Dunkel, R. L. Thiemann, J. Leibowitz, M. Zijlstra, and R. Jaenisch. 1993. Abrogation of resistance to Theiler's virus-induced demyelination in H-2b mice deficient in β2-microglobulin. J. Immunol. 151:266-276.
34. Rodriguez, M., J. Leibowitz, and C. S. David. 1986. Susceptibility to Theiler's virus-induced demyelination. Mapping of the gene within the H-2D region. J. Exp. Med. 163:620-631.
35. Samland, H., S. Huitron-Resendiz, E. Masliah, J. Criado, S. J. Henriksen, and I. L. Campbell. 2003. Profound increase in sensitivity to glutamatergic-but not cholinergic agonist-induced seizures in transgenic mice with astrocyte production of IL-6. J. Neurosci. Res. 73:176-187.
36. Smith, C. E., T. N. Eagar, J. L. Strominger, and S. D. Miller. 2005. Differential induction of IgE-mediated anaphylaxis after soluble versus cell-bound tolerogenic peptide therapy of autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA 102:9595-9600.
37. Sospedra, M., and R. Martin. 2005. Immunology of multiple sclerosis. Annu. Rev. Immunol. 23:683-747.
38. Tompkins, S. M., J. Padilla, M. C. Dal Canto, J. P. Ting, L. Van Kaer, and S. D. Miller. 2002. De novo central nervous system processing of myelin antigen is required for the initiation of experimental autoimmune encephalomyelitis. J. Immunol. 168:4173-4183.
39. Wiendl, H., and B. C. Kieseier. 2003. Disease-modifying therapies in multiple sclerosis: an update on recent and ongoing trials and future strategies. Expert Opin. Investig. Drugs 12:689-712.
40. Wood, K. J., and B. Sawitzki. 2006. Interferon gamma: a crucial role in the function of induced regulatory T cells in vivo. Trends Immunol. 27:183-187.
41. + cytotoxic T cell responses to myelin basic protein in multiple sclerosis. J. Immunol. 172:5120-5127.